Entac Medical is a technology company.
Entac Medical has raised $3.8M across 3 funding rounds.
Entac Medical has raised $3.8M in total across 3 funding rounds.
Entac Medical is a digital health company developing wearable devices that use predictive analytics and AI to analyze biological acoustic signals, forecasting patient adverse events like postoperative ileus (POI) and gastrointestinal impairment (GII).[1][2][4] Their key products, such as PrevisEA and Previs CDP, attach non-invasively to patients post-surgery to detect biomarkers, improving outcomes, reducing hospital readmissions exceeding 20%, and lowering care costs for healthcare providers.[1][4] Founded in 2015 and based in Memphis, Tennessee, the company has raised about $4.25M in Series B funding, remains operational with under 25 employees, and holds patents in acoustic signal analysis for conditions like acute pain and digestive disorders.[4][5]
Entac Medical was co-founded in 2015 by Buddy Lyons (CEO) and Dr. John Cromwell (CMO/CTO), emerging from University of Tennessee technology aimed at addressing GII, which affects about 25% of major abdominal surgery patients and drives high readmission rates.[4][8] The idea stemmed from acoustic biomarkers validated in studies, like a 2019 podium presentation at the American College of Surgeons showing PrevisEA's prospective prediction of POI.[1] Early challenges included financial hurdles—running out of money twice—but persistence led to pivotal moments like $4M funding in Series B (last raised ~2020) and strategic pivots toward commercialization via risk-free hospital trials.[4][5][8]
Entac Medical rides the predictive digital health wave, leveraging AI/IoT wearables amid rising post-surgical complications (20%+ readmissions) and healthcare cost pressures.[1][2][4] Timing aligns with maturing acoustic biomarker research from academic origins (UT) and FDA-adjacent validations, amplified by post-2020 funding for AI-driven medtech.[4][8] Market forces like value-based care and hospital efficiency demands favor non-invasive tools reducing GII risks; Entac influences the ecosystem by pioneering audio analytics, potentially expanding to respiratory events and inspiring Iowa/Memphis medtech hubs through venture partnerships.[5][8]
Entac Medical's path forward hinges on scaling PrevisEA adoption via trials and data, targeting FDA clearance expansions and new indications like bronchospasms amid AI-health convergence.[4][8] Trends in proactive monitoring and acoustic IoT will accelerate growth, evolving their influence from POI prediction to comprehensive AE mitigation in surgery and beyond—positioning them as a nimble player in cost-saving digital health.[2][8] With validated tech and resilient founders, expect partnerships driving commercial momentum, tying back to their core mission of turning acoustic signals into lifesaving foresight.[1]
Entac Medical has raised $3.8M in total across 3 funding rounds.
Entac Medical's investors include Innova Memphis.
Entac Medical has raised $3.8M across 3 funding rounds. Most recently, it raised $3.0M Series B in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $3.0M Series B | Innova Memphis | |
| May 1, 2018 | $520K Series A | Innova Memphis | |
| Jul 1, 2015 | $250K Seed | Innova Memphis |